This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McMurray, J. Search for Related Content PubMed PubMed Citation Articles by McMurray, J. Pubmed/NCBI databases Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?

Why we need new strategies in CHF management

University of Glasgow, Glasgow, UK, j.mcmurray@ bio.gla.ac.uk

Despite recent improvements in drug therapy, the prevalence of congestive heart failure (CHF) continues to rise, as a result of the increasing proportion of older people in the population and factors such as greater survival rates after myocardial infarction. More effective management strategies for CHF are therefore needed urgently. The angiotensin II type 1 (AT₁)-receptor blockers might contribute to such strategies, offering placebo-like tolerability and showing promise in early trials of their use in CHF. Large-scale outcome studies, currently underway, will provide further evidence of the value of AT₁-receptor blockers in CHF. In addition, the involvement of specially trained nurses in patient education and monitoring should enhance compliance with both existing and novel therapies, and thus help to increase the overall efficacy of holistic strategies for CHF management.

Key Words: CHF management • nurse intervention • AT1-receptor blockers • candesartan cilexetil

References

• Berry C., McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 1999;16:247-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602.[Free Full Text]
• Ho KKL, Anderson KM, Kannel WB, Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.[Abstract/Free Full Text]
• McDonagh TA, Morrison CE, Lawrence A. et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McMurray JV, McDonagh TA, Davie AP, Cleland JGF, Francis CM, Morrison, C. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998;19:842-6.[Web of Science][Medline] [Order article via Infotrieve]
• Remme WJ Present treatment options in congestive heart failure. Heart 1998;79 Suppl 2:S24-S28.[Web of Science][Medline] [Order article via Infotrieve]
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).NEnglJMed 1987;316:1429-35.[Abstract]
• Packer M., Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.ATLAS Study Group. Circulation 1999;100:2312-8.[Abstract/Free Full Text]
• Garg R., Yusuf S., for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-5.[Abstract/Free Full Text]
• Packer M., Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.[Abstract/Free Full Text]
• Cardiac Insufficiency Bisoprolol Study II trial group. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hjalmarson A., Goldstein S., Fagerberg B. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302.[Abstract/Free Full Text]
• McMurray JJ Major beta blocker mortality trials in chronic heart failure: a critical review. Heart 1999;82 Suppl 4:IV14-22.[Medline] [Order article via Infotrieve]
• Pitt B., Zannad F., Remme WJ et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
• The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.[Abstract/Free Full Text]
• Watson RDS, Gibbs CR, Lip GYH ABC of heart failure: clinical features and complications. BMJ 2000;320:236-9.[Free Full Text]
• Davie AP, MacMurray JJ ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians? Postgrad Med J 1999;75:219-22.[Abstract/Free Full Text]
• McColl A., Roderick P., Gabbay J., Smith H., Moore M. Performance indicators for primary care groups: an evidence based approach. BMJ 1998;317:1354-60.[Free Full Text]
• Stewart S., Pearson S. Uncovering a multitude of sins: medication management in the home post acute hospitalisation among the chronically ill. Aust NZ J Med 1999;29:220-7.[Web of Science][Medline] [Order article via Infotrieve]
• Leider HL Heart failure and disease management. Am J Manag Care 1998;4 (6 Suppl):S343-8.[Web of Science][Medline] [Order article via Infotrieve]
• McMurray JJV, Stewart S. Nurse led, multidisciplinary intervention in chronic heart failure. [Editorial] Heart 1998;80:430-1.
• Rich MW, Beckham V., Wittenberg C., Leven CL, Freedland KE, Carney RM A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.[Abstract/Free Full Text]
• Stewart S., Marley JE, Horowitz JD Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999;354:1077-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• JaarsmaT., Halfens R., Huijer A-S H. et al. Effects of education and support on self-care and resource utilization in patients with heart failure. Eur Heart J 1999;20:673-82.[Abstract/Free Full Text]
• Campbell RL, Banner R., Konick-McMahan J., Naylor MD Discharge planning and home follow-up of the elderly patient with heart failure. Nurs Clin North Am 1998;33:497-513.[Web of Science][Medline] [Order article via Infotrieve]
• Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.[Abstract/Free Full Text]
• Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cohn JN, Tognoni G., Glazer RD, Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, and angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Swedberg K., Pfeffer M., Granger C. et al. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-82.[CrossRef][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 1 suppl, 12-16 (2000)
DOI: 10.3317/jraas.2000.027


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McMurray, J. Search for Related Content PubMed PubMed Citation Articles by McMurray, J. Pubmed/NCBI databases Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?